found that nivolumab, a mAb that binds to PD-1, had fewer toxic effects compared with standard therapy (chemotherapy or cetuximab) and prolonged survival rates in patients that had disease progression after platinum-based chemotherapy treatment in HNSCC (50). Here, PDCD1 is linked to head and neck squamous cell carcinoma.